A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older
Latest Information Update: 21 Jan 2025
At a glance
- Drugs MRNA-1010 (Primary) ; GSK 2321138A
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Moderna Therapeutics
Most Recent Events
- 16 May 2024 This trial has been Completed in Poland, According to European Clinical Trials Database record.
- 16 Feb 2024 This trial has been Completed in Denmark, According to European Clinical Trials Database record.
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.